Association of lung function with coronary heart disease and cardiovascular disease outcomes in elderly: The Rancho Bernardo study  by Lee, Hwa Mu et al.
Respiratory Medicine (2014) 108, 1779e1785Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier .com/locate/rmedAssociation of lung function with coronary
heart disease and cardiovascular disease
outcomes in elderly: The Rancho Bernardo
study
Hwa Mu Lee a,b,*, Michael A. Liu b, Elizabeth Barrett-Connor c,
Nathan D. Wong ba Division of Pulmonary and Critical Care Medicine, University of California, Irvine, CA, USA
b Heart Disease Prevention Program, University of California, Irvine, CA, USA
c Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA, USAReceived 11 June 2014; accepted 26 September 2014
Available online 6 October 2014KEYWORDS
Pulmonary function
test;
Coronary heart
disease;
Cardiovascular
disease;
Epidemiology* Corresponding author. Departmen
Irvine, CA 92697-4101, USA.
E-mail address: leehwamumd@gm
http://dx.doi.org/10.1016/j.rmed.201
0954-6111/ª 2014 Elsevier Ltd. All rigSummary
Introduction: Lung function is inversely associated with coronary heart disease (CHD) and car-
diovascular disease (CVD). We evaluated the prospective association of reduced lung function
by spirometry and CHD or CVD events in older community-dwelling adults.
Methods: We studied 1548 participants (mean age 73.6  9.2 years, 42% males) from the
Rancho Bernardo Study using age, sex, and risk-factor adjusted Cox regression to assess pulmo-
nary function (FEV1, FVC, and FEV1/FVC ratio) as a predictor of CHD and CVD events followed
for up to 22 years.
Results: Of CVD risk factors, older age, male sex, current/past smoking, physical exercise
(<3 a week), and prevalent CVD predicted an increased risk of CHD and CVD. Higher
FEV1 and FVC were each associated with a decreased risk of CHD [HR 0.80 (0.73e0.88) for
both FEV1 and FVC, per SD, p < 0.01] and CVD [HR 0.82 (0.74e0.91) for both FEV1 and
FVC, per SD, p < 0.01]. Those in the lowest quartiles of FEV1 and FVC had hazard ratios
of 1.68 (1.33e2.13) and 1.55 (1.21e2.00) respectively for CHD and 1.74 (1.34e2.25) and
1.49 (1.13e1.96) respectively for CVD (all p < 0.01, relative to those in the highest quar-
tile). Similar findings were observed for CHD and CVD mortality. Sex- and age-stratified an-
alyses showed the strongest associations for CHD and CVD events in women and in the oldest
participants.t of Medicine, Heart Disease Prevention Program, C240 Medical Sciences, University of California,
ail.com (H.M. Lee).
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1780 H.M. Lee et al.Conclusions: FEV1 and FVC are inversely associated with risk of future CHD and CVD events
in older community-dwelling adults and may add to CVD risk stratification in the elderly.
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In spite of the current evidence-based approaches to car-
diovascular disease (CVD) reduction, CVD and coronary
heart disease (CHD) remain the leading cause of mortality
in many industrialized countries. Previous epidemiological
studies have shown reduced lung function is a significant
predictor of CHD and CVD mortality [1e3], as well as with
all-cause mortality [4e6]. In one study of non-smokers,
poor lung function was shown to be a better predictor of
CVD and total mortality than established cardiovascular risk
factors such as serum cholesterol [7].
Chronic obstructive pulmonary disease (COPD) is the
third leading cause of death and affects 65 million world-
wide, and the primary cause of COPD is tobacco smoke [8].
Its predictive capacity for cardiovascular disease incidence
and mortality has been well documented in the past
[9e11]. Because spirometry is the usual prognostic tool for
diagnosing COPD and its severity, it serves as a common risk
factor in evaluating the association of lung function with
CHD and CVD. As early as 1983, the Framingham Study
identified FVC as a prognostic indicator for CVD, in which
different FVC indexes could vary the risk of CVD death by a
three-to four-fold range [1]. Reduced FEV1 has also been
shown to predict cardiovascular morbidity and mortality in
other studies [3].
Our study evaluates the association of reduced lung
function and CVD or CHD events within the Rancho Ber-
nardo prospective study of CVD, a well-established cohort
of older predominantly Caucasian adults. No study has been
published on the association of lung function and CVD in the
Rancho Bernardo study cohort, and there are limited data
on the long-term prognostic significance of lung function in
population-based cohorts of older adults accounting for
prevalent CVD.
Methods
Between 1972 and 1974, 6629 adults representing 82% of
adult residents in Rancho Bernardo, a suburban Southern
California community, participated in the baseline exami-
nation of the Rancho Bernardo Heart and Chronic Disease
Study (RBS) [12]. Nonrespondents tended to have more CVD
and history of smoking, but less hyperlipidemia and family
history of CVD [13]. Residents were followed up in 1984e87
when 2479 participants attended a follow-up visit, and
again in 1988e91 when new data on cardiovascular risk
factors and pulmonary function (1988e91) were obtained.
We studied 1548 participants from the Rancho Bernardo
community-based cohort (mean age 73.6  9.2 years, 42%
males, primarily Caucasian) to assess pulmonary risk factors
associated with CHD and CVD events. We also includeddemographic and diverse health-related information
including body mass index, blood pressure, cholesterol,
diabetes, physical exercise, smoking, and pulmonary func-
tion tests. Pulmonary function tests were performed using a
water-sealed spirometer (Warren E. Collins, Eagle models,
Braintree, MA) by a specially trained graduate student
(Catherine Frette) who adhered to the 1987 American
Thoracic Society guidelines [14] and performed from three
to six tests to satisfy the ATS standards of acceptability and
reproducibility. RBS participants were followed for a
maximum of 22 years after spirometry. All participants gave
written informed consent; the study was approved by the
institutional review board of the University of California,
San Diego.
Chronic obstructive pulmonary disease (COPD) risk
groups were categorized as none (FEV1/FVC >70%), mild
(FEV1/FVC <70%, FEV1 80%), and moderate/severe (FEV1/
FVC< 70%, FEV1 <80%) according to the GOLD (Global
Initiative for Chronic Obstructive Pulmonary Disease)
criteria. Moderate and severe categories were combined
due to the number of participants within these groups.
Prevalent CVD was defined as physician-diagnosed
myocardial infarction, coronary artery revascularization,
congestive heart failure, stroke or transient ischemic
attack, carotid surgery, peripheral arterial surgery, or
physician-diagnosed intermittent claudication. Total (or
incident) CHD and CVD refer to time of non-fatal or fatal
CHD or CVD, whichever occurred first. Non-fatal CHD was
defined as heart attack, coronary bypass, or angioplasty,
while CVD additionally included stroke, TIA, and peripheral
artery revascularization. Classification of incident CHD and
CVD events were based on history, physician diagnosis,
and/or ECG criteria with vital status confirmed by death
certificates with underlying cause of death coded by a
certified nosologist using ICD-9. Validation of self-reported
heart attack (by chest pain, enzyme elevation, and ECG)
was achieved for 72% of a subset for whom hospital records
could be obtained.
All analyses were done using SAS version 9.1.3 (SAS
institute, Cary, NC). Analysis of variance (ANOVA) was used
to compare means between different COPD risk groups for
continuous variables, and chi-squared test of proportions
was used to compare proportions between the risk groups
for categorical variables. We also calculated CHD and CVD
mortality per 1000 person years associated with quartile of
FVC, FEV1, and ratio of FEV1/FVC. Cox proportional hazards
regression was used to determine the risk of total CHD or
CVD from the standard CVD risk factors: age, sex, systolic
blood pressure, diastolic blood pressure, body mass index,
high density lipoprotein-cholesterol (HDL-C), low density
lipoprotein (LDL-C), diabetes, smoking, exercise, COPD,
and prevalent CVD, both adjusted and unadjusted for
covariates. Additionally, we used Cox regression to assess
Table 1 Means and proportions for individuals with different severities of COPD.
Total
(n Z 1548)
100%
No COPD
(n Z 1165)
75.3%
Mild COPD
(n Z 252)
16.3%
Moderate and
severe COPD
(n Z 131) 8.5%
p Value
Means  Standard Deviation
Age (yr) 73.6  9.2 72.8  9.3 75.4  8.6 77.1  8.2 <0.0001***
SBP (mmHg) 135.7  20.3 135.1  20.4 136.9  20.7 138.7  18.4 0.0303*
DBP (mmHg) 75.8  9.2 75.7  9.2 75.7  9.4 75.9  9.1 0.8788
BMI (kg/m2) 25.1  3.7 25.3  3.8 24.2  3.3 24.6  4.0 0.0002***
Cholesterol (mg/dL) 222.1  39.9 224.6  40.0 213.0  37.6 218.1  40.4 0.0006***
HDL (mg/dL) 62.7  18.7 62.6  18.6 62.6  19.4 63.7  18.2 0.5835
LDL (mg/dL) 136.4  36.7 138.6  37.3 128.0  33.4 131.9  35.0 0.0003***
FEV1 (L) 2.3  0.8 2.4  0.7 2.3  0.7 1.2  0.5 <0.0001***
FVC (L) 3.1  0.9 3.1  0.9 3.5  1.0 2.4  0.8 0.0002***
FEV1/FVC ratio*100 74.2  10.4 78.7  5.0 64.5  4.6 52.8  13.7 <0.0001***
Follow-up CHD incidence (yr) 10.5  5.8 11.0  5.7 9.7  5.6 7.9  5.4 <0.0001***
Follow-up CVD incidence (yr) 10.1  5.8 10.6  5.8 9.3  5.6 7.6  5.3 <0.0001***
Follow-up mortality, CHD or CVD (yr) 12.2  5.9 12.8  5.7 11.3  5.8 8.6  5.7 <0.0001***
Proportions [%(n)]
Male 41.5 (642) 37.8 (440) 56.4 (142) 45.8 (131) <0.0001***
Diabetes 12.5 (193) 12.9 (150) 10.3 (26) 13.0 (17) 0.5283
Current smokers 9.1 (141) 6.8 (79) 15.5 (39) 17.6 (23) <0.0001***
Past smokers 47.8 (740) 44.3 (516) 56.8 (143) 61.8 (81)
Ex 3 a week 34.0 (527) 36.4 (424) 31.8 (80) 17.6 (23) <0.0001***
CHD death 11.2 (173) 10.3 (120) 13.1 (33) 15.3 (20) 0.1324
CVD death 26.7 (413) 24.1 (281) 32.5 (82) 38.2 (50) 0.0002***
Prevalent CHD 18.4 (284) 16.7 (195) 21.0 (53) 27.5 (36) 0.0052**
Prevalent CVD 24.2 (375) 22.4 (261) 25.8 (65) 37.4 (49) 0.0006***
Total CHD 19.8 (250) 19.5 (189) 22.1 (44) 17.9 (17) 0.6227
Total CVD 39.8 (467) 38.3 (346) 45.5 (85) 43.9 (36) 0.1388
*p < 0.05, **p < 0.01, ***p < 0.001.
Association of lung function with CHD and CVD outcomes 1781the relationship of pulmonary function tests [forced expi-
ratory volume in 1 min (FEV1), forced vital capacity (FVC),
and FEV1/FVC ratio] and total CHD and CVD. Standardized
hazard ratios (HR) are presented to compare the HR’s of
each measure per standard deviation increment. We then
categorized FEV1 and FVC values into quartiles andTable 2 Standard risk factors: standardized hazards ratio survi
Variables Total CHD HR CHD de
Unadjusted Adjusted Unadju
Age 1.74** 1.71** 1.79**
Gender (Male vs. Female) 1.12* 1.16* 1.17
Systolic blood pressure 1.14** 0.95 1.14**
Diastolic blood pressure 0.91** 0.98 0.90**
Body mass index 0.97 0.97 0.95
HDL Cholesterol 0.97 0.97 0.98
LDL cholesterol 0.94* 0.92** 0.96
Diabetes (Yes vs. No) 1.24* 1.06 1.24*
Smoking (Current/Past vs. Never) 1.06 1.14** 1.08
Exercise 3 a week (Yes vs. No) 0.60** 0.71** 0.64**
COPD (Yes vs. No) 1.31** 1.11* 1.40**
Prevalent CVD 1.51** 1.27** 1.27**
*p < 0.05, **p < 0.01, Hazards ratios are expressed per standard devcompared each the 1st, 2nd, and 3rd quartiles with the 4th
quartile using Cox regression for risk of CHD and CVD mor-
tality. Finally, we performed gender and age stratified an-
alyses for CHD and CVD outcomes. All tests of pulmonary
function variables were adjusted for standard CVD risk
factors.val analysis.
ath HR Total CVD HR CVD death HR
sted Adjusted Unadjusted Adjusted Unadjusted Adjusted
1.78** 1.64** 1.59** 1.54** 1.55**
1.32** 1.14* 1.18* 1.16* 1.33**
0.98 1.12** 0.96 1.06** 0.96
0.94 0.89** 0.95 0.89** 0.93
0.95 0.98 0.99 0.97 0.98
0.99 0.97 1.02 1.00 1.03
0.95 0.96 0.95 0.97 0.97
1.05 1.24* 1.06 1.15 1.01
1.16** 1.11* 1.17** 1.12* 1.17**
0.72** 0.60** 0.69** 0.64** 0.69**
1.16** 1.31** 1.09 1.31** 1.12*
1.05 1.91** 1.60** 1.21* 1.05
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T
a
b
le
3
P
u
lm
o
n
a
ry
fu
n
ct
io
n
e
st
im
a
te
s:
st
a
n
d
a
rd
iz
e
d
h
a
za
rd
s
ra
ti
o
su
rv
iv
a
l
a
n
a
ly
si
s.
A
d
ju
st
e
d
vs
.
u
n
a
d
ju
st
e
d
T
o
ta
l
C
H
D
H
R
(9
5%
C
I)
C
H
D
d
e
a
th
H
R
(9
5%
C
I)
T
o
ta
l
C
V
D
H
R
(9
5%
C
I)
C
V
D
d
e
a
th
H
R
(9
5%
C
I)
V
a
ri
a
b
le
s
U
n
a
d
ju
st
e
d
A
d
ju
st
e
d
U
n
a
d
ju
st
e
d
A
d
ju
st
e
d
U
n
a
d
ju
st
e
d
A
d
ju
st
e
d
U
n
a
d
ju
st
e
d
A
d
ju
st
e
d
F
E
V
1
(A
ct
u
a
l)
0.
73
**
(0
.6
9
e
0.
78
)
0.
80
**
(0
.7
3e
0.
88
)
0.
74
**
(0
.6
9e
0.
79
)
0.
77
**
(0
.7
0
e
0.
85
)
0.
75
**
(0
.7
0
e
0.
81
)
0.
82
**
(0
.7
4e
0.
91
)
0.
80
**
(0
.7
5e
0.
86
)
0.
81
**
(0
.7
3
e
0.
90
)
F
V
C
(A
ct
u
a
l)
0.
80
**
(0
.7
5
e
0.
84
)
0.
80
**
(0
.7
3e
0.
88
)
0.
81
**
(0
.7
7e
0.
86
)
0.
79
**
(0
.7
2
e
0.
87
)
0.
82
**
(0
.7
7
e
0.
87
)
0.
82
**
(0
.7
4e
0.
91
)
0.
86
**
(0
.8
1e
0.
92
)
0.
82
**
(0
.7
4
e
0.
91
)
F
E
V
1
/F
V
C
ra
ti
o
0.
83
**
(0
.7
9
e
0.
88
)
0.
96
(0
.9
0e
1.
03
)
0.
81
**
(0
.7
7e
0.
86
)
0.
93
*
(0
.8
8e
0.
99
)
0.
83
**
(0
.7
8
e
0.
89
)
0.
97
(0
.9
0e
1.
04
)
0.
85
**
(0
.7
9e
0.
90
)
0.
95
(0
.8
9
e
1.
03
)
A
d
ju
st
e
d
,
st
ra
ti
fi
e
d
b
y
ge
n
d
e
r
V
a
ri
a
b
le
s
M
a
le
F
e
m
a
le
M
a
le
F
e
m
a
le
M
a
le
F
e
m
a
le
M
a
le
F
e
m
a
le
F
E
V
1
(A
ct
u
a
l)
0.
82
**
(0
.7
1
e
0.
93
)
0.
81
**
(0
.7
1e
0.
94
)
0.
82
**
(0
.7
1e
0.
94
)
0.
73
**
(0
.6
3
e
0.
83
)
0.
84
*
(0
.7
3e
0.
97
)
0.
82
*
(0
.7
1
e
0.
96
)
0.
88
(0
.7
5e
1.
03
)
0.
74
**
(0
.6
4
e
0.
86
)
F
V
C
(A
ct
u
a
l)
0.
82
**
(0
.7
3
e
0.
93
)
0.
81
**
(0
.7
0e
0.
93
)
0.
85
*
(0
.7
6e
0.
96
)
0.
73
**
(0
.6
4
e
0.
84
)
0.
84
**
(0
.7
3
e
0.
96
)
0.
82
*
(0
.7
0
e
0.
96
)
0.
90
(0
.7
8e
1.
03
)
0.
74
**
(0
.6
4
e
0.
86
)
F
E
V
1
/F
V
C
ra
ti
o
0.
94
(0
.8
4e
1.
05
)
0.
96
(0
.8
9e
1.
04
)
0.
91
(0
.8
2e
1.
02
)
0.
93
(0
.8
6
e
1.
01
)
0.
95
(0
.8
5e
1.
07
)
0.
96
(0
.8
7e
1.
05
)
0.
95
(0
.8
4e
1.
08
)
0.
94
(0
.8
6
e
1.
03
)
A
d
ju
st
e
d
,
st
ra
ti
fi
e
d
b
y
m
e
d
ia
n
a
ge
V
a
ri
a
b
le
s
A
ge
7
4.
2
A
ge
>
74
.2
A
ge
7
4.
2
A
ge
>
74
.2
A
ge
7
4.
2
A
ge
>
74
.2
A
ge
7
4.
2
A
ge
>
74
.2
F
E
V
1
(A
ct
u
a
l)
0.
83
**
(0
.7
3
e
0.
95
)
0.
62
**
(0
.5
4e
0.
70
)
0.
82
**
(0
.7
2e
0.
93
)
0.
59
**
(0
.5
2
e
0.
67
)
0.
86
*
(0
.7
5e
0.
99
)
0.
63
**
(0
.5
4e
0.
72
)
0.
85
*
(0
.7
5e
0.
97
)
0.
64
**
(0
.5
5
e
0.
75
)
F
V
C
(A
ct
u
a
l)
0.
85
*
(0
.7
5e
0.
97
)
0.
61
**
(0
.5
4e
0.
70
)
0.
86
*(
0.
76
e
0.
97
)
0.
60
**
(0
.5
3
e
0.
68
)
0.
89
(0
.7
8e
1.
01
)
0.
61
**
(0
.5
3e
0.
70
)
0.
89
(0
.7
8e
1.
00
)
0.
64
**
(0
.5
5
e
0.
74
)
F
E
V
1
/F
V
C
ra
ti
o
0.
73
(0
.8
3e
1.
04
)
0.
94
(0
.8
7e
1.
02
)
0.
90
*(
0.
81
e
1.
00
)
0.
92
*(
0.
85
e
1.
00
)
0.
93
(0
.8
2e
1.
05
)
0.
95
(0
.8
7e
1.
04
)
0.
92
(0
.8
2e
1.
03
)
0.
95
(0
.8
6
e
1.
05
)
V
a
ri
a
b
le
s
a
d
ju
st
e
d
fo
r
st
a
n
d
a
rd
ri
sk
fa
ct
o
rs
:
a
ge
,
sy
st
o
li
c
b
lo
o
d
p
re
ss
u
re
,
d
ia
st
o
li
c
b
lo
o
d
p
re
ss
u
re
,
b
o
d
y
m
a
ss
in
d
e
x,
H
D
L,
LD
L,
se
x,
d
ia
b
e
te
s,
sm
o
ki
n
g,
e
xe
rc
is
e
,
a
n
d
p
re
va
le
n
t
C
V
D
,
*p
<
0.
05
,
**
p
<
0.
01
,
H
a
za
rd
s
ra
ti
o
s
a
re
e
xp
re
ss
e
d
p
e
r
st
a
n
d
a
rd
d
e
vi
a
ti
o
n
.
1782 H.M. Lee et al.Results
In our study, there were significant differences in risk fac-
tors according to COPD severity. With increasing COPD
group severity, the following trends were observed: older
age, lower FEV1, lower FVC, higher rate of CHD/CVD death,
higher proportion of CVD death, higher proportion of
prevalent CHD/CVD, higher proportion of current and past
smokers, and lower proportion of those who reported that
they exercised regularly (Table 1).
Of the standard risk factors, age, male sex, current/past
smoking, <3 a week physical exercise, and prevalent CVD
were significantly associated with total CHD and CVD, in
addition to higher LDL-C and having COPD for only total
CHD (Table 2). When controlled for standard risk factors,
higher FEV1 and FVC were significantly associated with
decreased risk of both CHD [HR 0.80 (0.73e0.88) for FEV1
and FVC, per SD, p < 0.01] and CVD [HR 0.82 (0.74e0.91)
for FEV1 and FVC, per SD, p < 0.01] (Table 3). Of note,
since FEV1 and FVC are often adjusted for height, adjust-
ment for height instead of BMI resulted in virtually iden-
tical results (data not shown). Additionally, the effects
appear stronger in women and in older persons after ad-
justments (Table 3). The upper cutpoints for the quartiles
of FEV1 were 1.80 L, 2.25 L, and 2.78 L, and the upper
cutpoints for the quartiles of FVC were 2.41 L, 2.98 L, and
3.70 L. Those in the lowest quartiles of FEV1 and FVC had
hazard ratios of 1.68 (1.33e2.13) and 1.55 (1.21e2.00)
respectively for CHD and hazards ratios of 1.74 (1.34e2.25)
and 1.49 (1.13e1.96) for CVD (all p < 0.01, relative to
those in the highest quartile) (Table 4). The FEV1/FVC ratio
was inversely associated with CHD and CVD events in un-
adjusted analyses, but not after adjustment for standard
risk factors and prevalent CVD.
We attained similar results when isolating the CHD and
CVD mortality outcomes specifically. Age (HR 1.78 CHD/
1.55 CVD, per SD, p < 0.01) and sex (HR 1.32 CHD/1.33 CVD,
male vs. female, p < 0.01) had the strongest positive as-
sociations, while exercise 3 a week (0.72 CHD/0.69 CVD,
p < 0.01) had the strongest negative association. A history
of COPD was significantly associated with CHD but not CVD
death (Table 2). When controlled for standard risk factors,
higher FEV1 and FVC were significantly associated with
decreased risk of both CHD and CVD death. FEV1/FVC ratio
was only mildly associated with CHD death (Table 3). Those
in the lowest quartiles of FEV1 and FVC had the highest
hazards ratios for CHD and CVD death (all p < 0.01, relative
to those in the highest quartile) (Table 4).
Secondary analyses were also conducted with the prev-
alent CVD cases omitted from the cross-sectional analyses
(new sample 1173). Adjusted hazards ratios for FEV1 and
FVC were 0.80 (0.72e0.89) and 0.81 (0.73e0.90) respec-
tively for CHD death and 0.83 (0.74e0.94) and 0.84
(0.75e0.94) respectively for CVD death, all p < 0.01. FEV1/
FVC ratio was not statistically significant for either
endpoint. In quartile analysis, those in the lowest quartiles
of FEV1 and FVC had hazard ratios of 1.54 (1.17e2.01) and
1.64 (1.24e2.18) respectively for CHD death and hazards
ratios of 1.54 (1.14e2.07) and 1.63 (1.19e2.22) for CVD
Death (all p < 0.01, compared to those in the highest
quartile).
Table 4 Adjusted hazards ratio on risk of CHD/CVD outcomes.
Total CHD HR (95% CI) CHD death HR (95% CI) Total CVD HR (95% CI) CVD death HR (95% CI)
FEV1
FEV1 Q3 vs. Q4 1.26* (1.06e1.51) 1.23* (1.03e1.47) 1.27* (1.05e1.54) 1.18 (0.97e1.44)
FEV1 Q2 vs. Q4 1.20 (0.98e1.46) 1.25* (1.02e1.52) 1.15 (0.92e1.43) 1.19 (0.95e1.48)
FEV1 Q1 vs. Q4 1.68** (1.33e2.13) 1.83** (1.45e2.31) 1.74** (1.34e2.25) 1.75** (1.35e2.26)
FVC
FVC Q3 vs. Q4 1.19 (1.00e1.43) 1.16 (0.97e1.38) 1.11 (0.92e1.35) 1.13 (0.93e1.38)
FVC Q2 vs. Q4 1.21 (0.97e1.51) 1.20 (0.96e1.50) 1.06 (0.83e1.37) 1.11 (0.87e1.43)
FVC Q1 vs. Q4 1.55** (1.21e2.00) 1.69** (1.32e2.16) 1.49** (1.13e1.96) 1.68** (1.28e2.21)
Variables adjusted for standard CVD risk factors: age, systolic blood pressure, diastolic blood pressure, body mass index, HDL, LDL, sex,
diabetes, smoking, exercise, and prevalent CVD, *p < 0.05, **p < 0.01.
Association of lung function with CHD and CVD outcomes 1783From highest to lowest quartiles of FVC and FEV1, rates
of CHD mortality (per 1000 person years) ranged from 1.53
to 2.54 for FVC and 1.38 to 3.07 for FEV1 and rates of CVD
mortality from 3.76 to 6.62 for FVC and 3.23 to 7.46 for
FEV1 (Figs. 1 and 2). For the FEV1/FVC ratio from highest to
lowest quartiles, rates of CHD mortality varied from 1.48 to
2.80 and CVD mortality from 4.39 to 7.04, respectively.Discussion
Our study is the first to evaluate the long-term prognostic
significance of lung spirometry in a large and relatively
healthy community-dwelling cohort of older adults fol-
lowed for up to 22 years. We report here the potential
clinical utility of these measures examining the association
between classic CVD risk factors and the severity of COPD.
We demonstrated the strong and similar prognostic value of
FEV1 and FVC for total CHD and CVD and for mortality from
CHD and CVD. Specifically, increased COPD severity,
defined by spirometry, was significantly correlated with
many CVD risk factors including age, SBP (systolic blood
pressure), male sex, lack of exercise, and current or pastFigure 1 Quartile comparison of pulmonarsmoking and was significantly associated with increased
CVD mortality.
Although several CVD risk factors such as cholesterol and
BMI showed significant differences among COPD severity
groups, there were no clear trends. While past studies have
suggested that cholesterol is a risk factor for CVD but not
COPD [15], BMI has been previously established as an in-
dependent prognostic factor in all-cause mortality among
COPD individuals [16e19].
After adjustment, many of the same COPD severity
factors (older age, male sex, current/past smoking, <3 a
week physical exercise) were significantly associated with
incidence/death of CHD and CVD. Prevalent CVD was a
predictor of future CHD or CVD cases, but not mortality.
The presence of COPD itself was significantly associated
with higher risk of CHD incidence and death as well as CVD
death. Both FEV1 and FVC were strongly and inversely
associated with the risk of CHD and CVD outcomes after
adjusting for standard risk factors; however, the FEV1/FVC
ratio commonly used in diagnosis of lung disease, while
predictive of outcomes in unadjusted analyses, did not
remain significantly associated with outcomes after
adjustment for risk factors and CVD. It is possible thaty function indicators with CHD mortality.
Figure 2 Quartile comparison of pulmonary function indicators with CVD mortality.
1784 H.M. Lee et al.reduced variability in the FEV1/FVC ratio in our largely
healthy cohort (75% without COPD) and adjustment for risk
factors that could confound the relation of the FEV1/FVC
ratio with outcomes may explain this.
FVC has been suggested to add predictive power to CHD
mortality over traditional CHD risk factors [20]; the current
study confirms that higher FVC is associated with
decreased risk of CHD and CVD death after controlling for
standard cardiovascular risk factors. In the Framingham
study, Kannel et al. reported that risk of congestive heart
failure was significantly increased among those in the
lower quartiles of FVC; we similarly observed increased
CHD and CVD death among those with lower FVC in our
cohort. FEV1 is a well-studied risk factor for CVD
[1,3,19e26]; our study confirms these relationships and
found that the negative association was particularly
prominent in the highest risk quartile (Q1), which
increased the risks of CVD death and CHD death nearly
two-fold compared to the lowest risk quartile (Q4). The
magnitude of FEV1 and FVC in predicting these outcomes
was not impacted heavily by those without baseline CVD,
as indicated in our secondary analysis which yielded similar
numbers after excluding individuals with prevalent CVD.
Importantly, Lundback and colleagues in the Obstructive
Lung Disease in Northern Sweden (OLIN) Study have shown
the strong prognostic significance of COPD; the survival
after 20 years was only 19% in those with severe and very
severe COPD, and disease severity and concomitant
ischemic heart disease or heart failure at entry was
significantly predictive of death [27].
We additionally performed analyses stratified by sex and
age, and reported that these associations were strongest
among women and older individuals in our study. Despite an
overall lower risk of CVD death in women in our study, the
strength of the inverse correlation of pulmonary function
with cardiovascular outcomes was slightly greater in
women which may have implications for preventative
measures in pulmonary disease treatment. The Framingham
study [1] reflects our results showing that women had
stronger associations than men of low vital capacity indexwith CVD incidence. The stronger associations among the
oldest individuals support the particular utility of using
spirometry to assess CVD risk as a primary prevention tool in
the elderly.
There are several strengths and limitations to our study.
Our measures of spirometry used three to six tests with the
ATS standard of acceptability and reproducibility, although
was limited by the single visit where lung function measures
were obtained. Thus, we were unable to examine the
prognostic significance of worsening of COPD as could be
possible from serial measures of pulmonary function [27].
Additionally, only a limited number of participants met the
classifications of moderate and severe COPD, so we had
limited statistical power to examine the impact of severe
COPD separately. Furthermore, the sample of upper middle
class, predominately older Caucasian participants, nearly
all of whom had health insurance, should not be general-
ized to more diverse populations. On the other hand,
baseline data were collected at a time when individuals of
this community were less informed about healthy lifestyle
habits or not taking effective medications for cholesterol
and blood pressure, making the associations less
confounded compared to more recent years, an advantage
compared to more contemporary cohorts.
In conclusion, FEV1 and FVC are inversely associated
with risk of future CHD and CVD outcomes in older
community-dwelling adults, largely independent of classic
cardiovascular risk factors, and may be useful measures for
risk stratification in older adults.Conflicts of interest
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